SEC Form 10-K filed by Indivior Pharmaceuticals Inc.
$INDV
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/6/2025 | $27.00 | Buy | H.C. Wainwright |
| 7/22/2025 | $20.00 | Buy | Jefferies |
| 1/28/2025 | $16.00 | Buy | Rodman & Renshaw |
| 7/23/2024 | $22.00 | Overweight | Piper Sandler |
| 4/3/2024 | $37.00 | Buy | Craig Hallum |
| 7/13/2023 | $35.00 | Outperform | Northland Capital |
4 - Indivior Pharmaceuticals, Inc. (0001625297) (Issuer)
4 - Indivior Pharmaceuticals, Inc. (0001625297) (Issuer)
4 - Indivior Pharmaceuticals, Inc. (0001625297) (Issuer)
Generated Record Quarterly and Full-Year Total SUBLOCADE® Net Revenue of $252 Million and $856 MillionAchieved Quarterly and Full-Year GAAP Net Income of $102 Million and $210 Million; Non-GAAP Quarterly and Full-Year Net Income of $107 Million and $320 MillionDelivered Record Quarterly and Full-Year Adjusted EBITDA of $142 Million and $428 MillionEntered Phase II of the Indivior Action Agenda – Accelerate – on January 1, 2026Authorized New $400 Million Share Repurchase ProgramReaffirmed Full-Year 2026 Financial Guidance Announced on January 8, 2026Conference Call at 8:00 A.M. EST Today RICHMOND, Va., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (NASDAQ:INDV) today
RICHMOND, Va., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (NASDAQ:INDV) today announced that it will participate in the following upcoming investor conferences: Barclays 28th Annual Global Healthcare Conference – Miami, FLJoe Ciaffoni, Chief Executive Officer, will host 1x1 / group meetings on Tuesday, March 10th. Joe Ciaffoni will also participate in a fireside chat on Tuesday, March 10th at 2:00 p.m. U.S. EST. Interested investors should contact their Barclays representative to schedule a meeting. The fireside chat will be publicly available and can be accessed using the following weblink: Barclays Webcast Link. 2026 Jefferies Biotech on the Beach Summit – Miami,
RICHMOND, Va., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (NASDAQ:INDV) today announced that it will report its fourth quarter and full-year 2025 financial results on Thursday, February 26, 2026, at 7:00 a.m. U.S. EST. Following the release of the financial results, Joe Ciaffoni, Chief Executive Officer, and other members of Indivior's leadership team will host a presentation via live webcast at 8:00 a.m. U.S. EST. Access to the Live Webcast Presentation: The webcast event and materials can be accessed on the "Investors" section of the company's website at www.indivior.com before the event begins. Live webcast link: https://edge.media-server.com/mmc/p/f78ufsat Par
H.C. Wainwright initiated coverage of Indivior with a rating of Buy and set a new price target of $27.00
Jefferies resumed coverage of Indivior with a rating of Buy and set a new price target of $20.00
Rodman & Renshaw initiated coverage of Indivior with a rating of Buy and set a new price target of $16.00
10-K - Indivior Pharmaceuticals, Inc. (0001625297) (Filer)
8-K - Indivior Pharmaceuticals, Inc. (0001625297) (Filer)
SCHEDULE 13G - Indivior Pharmaceuticals, Inc. (0001625297) (Subject)
4 - INDIVIOR PLC (0001625297) (Issuer)
4 - INDIVIOR PLC (0001625297) (Issuer)
4 - INDIVIOR PLC (0001625297) (Issuer)
Generated Record Quarterly and Full-Year Total SUBLOCADE® Net Revenue of $252 Million and $856 MillionAchieved Quarterly and Full-Year GAAP Net Income of $102 Million and $210 Million; Non-GAAP Quarterly and Full-Year Net Income of $107 Million and $320 MillionDelivered Record Quarterly and Full-Year Adjusted EBITDA of $142 Million and $428 MillionEntered Phase II of the Indivior Action Agenda – Accelerate – on January 1, 2026Authorized New $400 Million Share Repurchase ProgramReaffirmed Full-Year 2026 Financial Guidance Announced on January 8, 2026Conference Call at 8:00 A.M. EST Today RICHMOND, Va., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (NASDAQ:INDV) today
RICHMOND, Va., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (NASDAQ:INDV) today announced that it will report its fourth quarter and full-year 2025 financial results on Thursday, February 26, 2026, at 7:00 a.m. U.S. EST. Following the release of the financial results, Joe Ciaffoni, Chief Executive Officer, and other members of Indivior's leadership team will host a presentation via live webcast at 8:00 a.m. U.S. EST. Access to the Live Webcast Presentation: The webcast event and materials can be accessed on the "Investors" section of the company's website at www.indivior.com before the event begins. Live webcast link: https://edge.media-server.com/mmc/p/f78ufsat Par
Q3'25 Total Net Revenue of $314m, up 2% YOY; Q3'25 SUBLOCADE® Net Revenue of $219m, up 15% YOYAnnounces the Optimization of Rest of World (ROW) Business Discontinued the Sales and Marketing Support of OPVEE®Expect Annual Operating Expense Savings of at Least $150m in 2026On Track to Enter Phase II of the Indivior Action Agenda — Accelerate — January 1, 2026Conference Call Scheduled for Today at 8:00 A.M. EasternRICHMOND, Va., Oct. 30, 2025 /PRNewswire/ -- Indivior PLC (NASDAQ:INDV) today reported its financial results for the third quarter ended September 30, 2025, and provided a business update.
NEW YORK, Dec. 5, 2025 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, December 22, to coincide with the quarterly rebalance. The changes ensure that each index is more representative of its market capitalization range. The companies being removed from the S&P SmallCap 600 are no longer representative of the small-cap market space. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector Dec 22, 2025 S&P 500 Addition CRH CRH Mat
RICHMOND, Va., July 8, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq / LSE: INDV) today announced the appointment of Vanessa Procter as Executive Vice President of Corporate Affairs, effective July 7, 2025. Vanessa is a seasoned corporate affairs leader with extensive experience in the biopharmaceutical industry, and will be responsible for Corporate Communications, Government Affairs, Policy and Advocacy at Indivior. "We are excited to welcome Vanessa to the Indivior team," said Joe Ciaffoni, Chief Executive Officer. "Vanessa has an impressive track record of aligning teams to pr
RICHMOND, Va., June 24, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq / LSE: INDV) today announced the appointment of Tony Kingsley to the Board of Directors as an Independent Non-Executive Director, effective July 1, 2025. Mr. Kingsley was appointed pursuant to Indivior's relationship agreement with affiliates of Oaktree Capital Management, L.P., who supported his appointment. Tony Kingsley is an accomplished biopharmaceutical executive with a distinguished track record of building and leading organizations across multiple scientific disciplines, therapeutic areas, and stages of
SC 13G - INDIVIOR PLC (0001625297) (Subject)
SC 13G/A - INDIVIOR PLC (0001625297) (Subject)
SC 13D/A - INDIVIOR PLC (0001625297) (Subject)